Cargando…
Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial
This report describes the rationale and design of a study assessing tolvaptan in children with autosomal dominant polycystic kidney disease (ADPKD). Phase A is a 1-year, randomized, double-blind, placebo-controlled, multicenter trial. Phase B is a 2-year, open-label extension. The target population...
Autores principales: | Schaefer, Franz, Mekahli, Djalila, Emma, Francesco, Gilbert, Rodney D., Bockenhauer, Detlef, Cadnapaphornchai, Melissa A., Shi, Lily, Dandurand, Ann, Sikes, Kimberly, Shoaf, Susan E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565642/ https://www.ncbi.nlm.nih.gov/pubmed/31053954 http://dx.doi.org/10.1007/s00431-019-03384-x |
Ejemplares similares
-
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
por: Mekahli, Djalila, et al.
Publicado: (2023) -
Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019) -
The wind of change in the management of autosomal dominant polycystic kidney disease in childhood
por: Gimpel, Charlotte, et al.
Publicado: (2021) -
Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective
por: De Rechter, Stéphanie, et al.
Publicado: (2018) -
Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?
por: De Rechter, Stéphanie, et al.
Publicado: (2017)